RX

Recursion Pharmaceuticals IncNASDAQ RXRX Stock Report

Last reporting period 30 Jun, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

1.92

Small

Exchange

XNAS - Nasdaq

RXRX Stock Analysis

RX

Uncovered

Recursion Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-43/100

Low score

Market cap $B

1.92

Dividend yield

Shares outstanding

191.26 B

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 500 full-time employees. The company went IPO on 2021-04-16. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.

View Section: Eyestock Rating